Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of +25.00% and -3.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?